FDA seeks additional safety data from Eli Lilly for Foundayo to assess cardiovascular, liver, thyroid, and pediatric risks post-approval.

Nuvectis Pharma (NVCT) had a bit of a problem back in November of 2024 because that's when its stock traded lower by as much as 45% when it released data from its phase 1b study using NXP800 for the ...

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic ...

July 31 (Reuters) - U.S. drug distributor Cencora (COR.N), opens new tab said on Wednesday that additional data on patients, beyond what was initially identified, had been stolen in a cyberattack and ...